Loading stock data…
$8.95-0.06 (-0.67%)
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies.
Xilio Therapeutics, Inc. in the Healthcare sector is trading at $9.01 with a market capitalization of $59M. Wall Street consensus targets $20.00 (1 analysts), implying a +122.0% move over the next 12 months. The stock is currently 28% below its 52-week high of $12.59, remaining 5.1% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $18.69M↑ | $12.65M↓ | $13.69M↓ | $19.07M↑ | $8.08M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.49M↑ | -$14.11M↓ | -$11.84M↓ | -$1.93M↑ | -$14.37M |
| Net Income | -$6.37M↑ | -$9.53M↓ | $10.36M↑ | -$16.29M↓ | -$15.84M |
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-...